These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36521705)

  • 1. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay.
    Xiang Y; Zhai G; Li Y; Wang M; Chen X; Wang R; Xie H; Zhang W; Ge G; Zhang Q; Xu Y; Caflisch A; Xu J; Chen H; Chen L
    Int J Biol Macromol; 2023 Jan; 226():780-792. PubMed ID: 36521705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
    Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
    Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
    J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
    Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
    J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
    Borkotoky S; Dey D; Hazarika Z
    Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosensor-based active ingredient recognition system for screening potential small molecular Severe acute respiratory syndrome coronavirus 2 entry blockers targeting the spike protein from Rugosa rose.
    Yu W; Yi SZ; Jiang CY; Guan JW; Xue R; Zhang XX; Zeng T; Tang H; Chen W; Han B
    Biomed Chromatogr; 2024 Oct; 38(10):e5987. PubMed ID: 39126351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Potential Allosteric Site in the SARS-CoV-2 Spike Protein and Targeting Allosteric Inhibitor to Stabilize the RBD Down State using a Computational Approach.
    Li T; Yan Z; Zhou W; Liu Q; Liu J; Hua H
    Curr Comput Aided Drug Des; 2024; 20(6):784-797. PubMed ID: 37493168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
    Basit A; Ali T; Rehman SU
    J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.